title: Current State of Metal-Based Drugs for the Efficient Therapy of Lung Cancers and Lung Metastases.
abstract: Lung cancer is the second most common cancer in both men and women and thus a leading cause of cancer-related deaths worldwide. New efficient treatments especially for its advanced stages and metastases are desperately needed, particularly with regard to overcoming the resistance which thwarts the efficacy of most clinically established drugs such as the platinum complexes. Glimpses of hope are new metal-based drugs that have emerged over the past decade which displayed efficacy in patients with platinum-resistant tumors and metastases. This chapter provides an overview of the latest developments of such metal-based drugs against lung cancer.
authors.affiliation: Organic Chemistry Laboratory, University of Bayreuth, Universitätsstr. 30, 95447, Bayreuth, Germany. bernhard.biersack@uni-bayreuth.de.
authors.forename: Bernhard
authors.initials: B
authors.lastname: Biersack
authors.affiliation: Organic Chemistry Laboratory, University of Bayreuth, Universitätsstr. 30, 95447, Bayreuth, Germany.
authors.forename: Rainer
authors.initials: R
authors.lastname: Schobert
mesh_terms: D002945:Cisplatin / Q000627:therapeutic use; D004121:Dimethyl Sulfoxide / Q000031:analogs & derivatives / Q000627:therapeutic use; D005296:Ferrous Compounds / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000075163:Metallocenes; D008665:Metalloporphyrins / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000627:therapeutic use; D017975:Ruthenium Compounds
chemical_list: D005296:Ferrous Compounds; D000075163:Metallocenes; D008665:Metalloporphyrins; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; C113661:imidazolium-bis(imidazole)dimethylsulfoxideimidazotetrachlororuthenate(III); C437683:motexafin gadolinium; D002945:Cisplatin; C004998:ferrocene; D004121:Dimethyl Sulfoxide
keywords: Anticancer agents; Ferrocene derivatives; Gadolinium; Lung cancer; Lung metastasis; Multi-drug resistance; Platinum complexes; Ruthenium complexes; Tumor targeting